Leiva O, Hobbs G, Ravid K, Libby P. Cardiovascular Disease in Myeloproliferative Neoplasms: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol. 2022;4(2):166–82.

Article  PubMed  PubMed Central  Google Scholar 

Mehta D, Alimam S, McLornan DP, Henry JA, Ahmed S, Ghosh AK, et al. Cardiovascular risk in a contemporary cohort of patients with myeloproliferative neoplasms’. Curr Res Transl Med. 2023;72(1): 103420.

PubMed  Google Scholar 

Gerds AT, Gotlib J, Ali H, Bose P, Dunbar A, Elshoury A, et al. Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(9):1033–62. https://doi.org/10.6004/jnccn.2022.0046.

Article  PubMed  CAS  Google Scholar 

Baldini C, Moriconi FR, Galimberti S, Libby P, De Caterina R. The JAK-STAT pathway: an emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms. Eur Heart J. 2021;42(42):4389–400.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105(9):1135–43.

Article  PubMed  CAS  Google Scholar 

Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377(12):1119–31.

Article  PubMed  CAS  Google Scholar 

Hu YF, Chen YJ, Lin YJ, Chen SA. Inflammation and the pathogenesis of atrial fibrillation. Nat Rev Cardiol. 2015;12(4):230–43.

Article  PubMed  CAS  Google Scholar 

Vakhshoori M, Nemati S, Sabouhi S, Yavari B, Shakarami M, Bondariyan N, et al. Neutrophil to lymphocyte ratio (NLR) prognostic effects on heart failure; a systematic review and meta-analysis. BMC Cardiovasc Disord. 2023;23(1):555.

Article  PubMed  PubMed Central  Google Scholar 

Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379–90.

Article  PubMed  CAS  Google Scholar 

Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054–61.

Article  PubMed  CAS  Google Scholar 

Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108(10):3472–6.

Article  PubMed  CAS  Google Scholar 

Spivak JL. Myeloproliferative Neoplasms. N Engl J Med. 2017;376(22):2168–81.

Article  PubMed  CAS  Google Scholar 

Perner F, Perner C, Ernst T, Heidel FH. Roles of JAK2 in Aging, Inflammation, Hematopoiesis and Malignant Transformation. Cells. 2019;8(8):854. https://doi.org/10.3390/cells8080854.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Krecak I, Holik H, MoricPeric M, Zekanovic I, Coha B, ValovicicKrecak M, et al. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as prognostic biomarkers in polycythemia vera. Int J Lab Hematol. 2022;44(4):e145–8.

Article  PubMed  Google Scholar 

Kleppe M, Kwak M, Koppikar P, Riester M, Keller M, Bastian L, et al. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. Cancer Discov. 2015;5(3):316–31.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Pourcelot E, Trocme C, Mondet J, Bailly S, Toussaint B, Mossuz P. Cytokine profiles in polycythemia vera and essential thrombocythemia patients: clinical implications. Exp Hematol. 2014;42(5):360–8.

Article  PubMed  CAS  Google Scholar 

Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol. 2011;29(10):1356–63.

Article  PubMed  CAS  Google Scholar 

Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, et al. Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease. N Engl J Med. 2017;377(2):111–21.

Article  PubMed  PubMed Central  Google Scholar 

Sano S, Wang Y, Walsh K. Clonal Hematopoiesis and Its Impact on Cardiovascular Disease. Circ J. 2018;83(1):2–11.

Article  PubMed  PubMed Central  Google Scholar 

Jager R, Hoke M, Mayer FJ, Boden S, Englisch C, Ay C, et al. Combined Effects of Clonal Hematopoiesis and Carotid Stenosis on Cardiovascular Mortality. J Am Coll Cardiol. 2024;83(18):1717–27.

Article  PubMed  Google Scholar 

Kiefer KC, Cremer S, Pardali E, Assmus B, Abou-El-Ardat K, Kirschbaum K, et al. Full spectrum of clonal haematopoiesis-driver mutations in chronic heart failure and their associations with mortality. ESC Heart Fail. 2021;8(3):1873–84.

Article  PubMed  PubMed Central  Google Scholar 

Molinaro R, Sellar RS, Vromman A, Sausen G, Folco E, Sukhova GK, et al. The clonal hematopoiesis mutation Jak 2(V617F) aggravates endothelial injury and thrombosis in arteries with erosion-like intimas. Int J Cardiol. 2024;409: 132184.

Article  PubMed  Google Scholar 

Bhatt DL, Lopes RD, Harrington RA. Diagnosis and Treatment of Acute Coronary Syndromes: A Review. JAMA. 2022;327(7):662–75.

Article  PubMed  Google Scholar 

Solli CN, Chamat-Hedemand S, Elming H, Ngo A, Kjaer L, Skov V, et al. Coronary artery- and aortic valve calcifications in patients with Philadelphia-negative myeloproliferative neoplasms. Int J Cardiol. 2022;364:112–8.

Article  PubMed  Google Scholar 

Solli CN, Chamat-Hedemand S, Elming H, Ngo A, Kjaer L, Skov V, et al. High JAK2V617F variant allele frequency is associated with coronary artery but not aortic valve calcifications in patients with Philadelphia-negative myeloproliferative neoplasms. Eur J Haematol. 2023;111(3):400–6.

Article  PubMed  CAS  Google Scholar 

Kwok CS, Wong CW, Kontopantelis E, Barac A, Brown SA, Velagapudi P, et al. Percutaneous coronary intervention in patients with cancer and readmissions within 90 days for acute myocardial infarction and bleeding in the USA. Eur Heart J. 2021;42(10):1019–34.

Article  PubMed  Google Scholar 

Leiva O, Xia Y, Siddiqui E, Hobbs G, Bangalore S. Outcomes of Patients With Myeloproliferative Neoplasms Admitted With Myocardial Infarction: Insights From National Inpatient Sample. JACC CardioOncol. 2023;5(4):457–68.

Article  PubMed  PubMed Central  Google Scholar 

Leiva O, Beaman H, Brunner A, How J, Hobbs G. Abstract 11955: Hospital Readmission Outcomes After Myocardial Infarction Among Patients With Myeloproliferative Neoplasms. Circulation. 2023;148(Suppl_1):A11955-A. https://doi.org/10.1161/circ.148.suppl_1.11955.

Wu J, Fan Y, Zhao W, Li B, Pan N, Lou Z, et al. In-Hospital Outcomes of Acute Myocardial Infarction With Essential Thrombocythemia and Polycythemia Vera: Insights From the National Inpatient Sample. J Am Heart Assoc. 2022;11(24): e027352.

Article  PubMed  PubMed Central  Google Scholar 

Leiva O, Jenkins A, Rosovsky RP, Leaf RK, Goodarzi K, Hobbs G. Risk Factors for Death or Cardiovascular Events after Acute Coronary Syndrome in Patients with Myeloproliferative Neoplasms. Hematol Rep. 2023;15(2):398–404.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895–1032.

PubMed